Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5542MR)

This product GTTS-WQ5542MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5542MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4623MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ15333MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ2424MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ5032MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ12246MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7661MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ12515MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ6564MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW